Clinical Study Investigating the Effect of Sodium Nitroprusside Infusion on Thyroidal Function

Does Sodium Nitroprusside Infusion Affect Thyroidal Function in Patients Undergoing Coronary Artery Bypass Grafting, a Prospective Randomized Clinical Trial.

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00636584

Enrollment

106

Registered

2008-03-14

Start date

2008-02-29

Completion date

2008-03-31

Last updated

2008-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nitroprusside, Thyroid Hormones

Keywords

sodium nitroprusside, thyroid hormones, thoracic surgery

Brief summary

Whether use of SNP during cardiac surgery has any effect on thyroid function has not yet been investigated in humans. The aim of this study was to investigate the effects of SNP administration during the rewarming period of cardiac operations on circulating levels of thyroid hormones.

Interventions

DRUGsodium nitroprusside

sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations

DRUGplacebo

placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

Patients without history of: * thyroidal disease * hypertension * pulmonary disease * peripheral vascular disease * stroke * recent myocardial infarction within the week prior to operation * unstable angina pectoris * liver or kidney dysfunction * morbid obesity * cachexia * sulfonylurea intake

Exclusion criteria

* Patients who needed positive inotropic pharmacologic support during or after the operation * Patients who developed atrial fibrillation in the post operative period requiring amiodarone therapy * In addition, patients receiving any medication known to interfere with any step of thyroid hormone metabolism such as * amiodarone * propranolol * furosemide * non-steroidal anti-inflammatory agents * steroids * estrogens * antacids * diphenylhydantoin * spironolactone

Design outcomes

Primary

Measure	Time frame
free T3	on admission, prior to operation, at the beginning of CPB, following CPB, at first, third and fifth postoperative days

Secondary

Measure	Time frame
total T3	on admission, prior to operation, at the beginning of CPB, following CPB, on the first, third and fifth postoperative days

Countries

Turkey (Türkiye)

Contacts

Primary Contactalp aslan, md

alpslan@yahoo.com0905425179917

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026